J. M. Sanchez

A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)

Luis Paz‐Ares, J. M. Sanchez, A. García et al. · Journal of Clinical Oncology · 2006 · 162 citations

Medicine, Oncology, Pharmacology +17

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

R. Rosell, R. Gervais, A. Vergnenègre et al. · Journal of Clinical Oncology · 2011 · 148 citations

Medicine, Oncology, Pharmacology +16

Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial

Mark A. Socinski, Silvia Novello, J. M. Sanchez et al. · Journal of Clinical Oncology · 2006 · 100 citations

Medicine, Oncology, Pharmacology +15

Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics

Paloma Navarro, María J. Bueno, Ivana Zagorac et al. · Cell Reports · 2016 · 98 citations · Full text

Medicine, Cancer Biology, Oncology +12

Monitoring vascular normalization induced by antiangiogenic treatment with 18F‐fluoromisonidazole‐PET

Elena Hernández-Agudo, Tamara Mondejar, María Luisa Soto‐Montenegro et al. · Molecular Oncology · 2015 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17